Skip to main content
Top
Published in: Journal of Neurology 1/2019

01-01-2019 | Original Communication

Urinary symptoms, quality of life, and patient satisfaction in genetic and sporadic hereditary spastic paraplegia

Authors: Susanne A. Schneider, Viktoria E. Beckinger, Bettina Möller, Stephanie Knüpfer, Moritz Hamann, Günther Deuschl

Published in: Journal of Neurology | Issue 1/2019

Login to get access

Abstract

Background

Urinary involvement is common in hereditary spastic paraplegias (HSPs), but has rarely been assessed systematically.

Methods

We characterized urinary complaints in 71 German HSP patients (mean age 55.4 ± 13.9 years; mean disease duration 20.7 ± 14.3 years; 48% SPG4-positive) using validated clinical rating scales (SCOPA-AUT, ICIQ-SF, ICIQ-LUTSqol). Treatment history and satisfaction with medical care was also assessed.

Results

74.6% of patients had one or more urological problems, most commonly nocturia and urgency. Incontinence was more severe in women, correlating with SCOPA-AUT. Female gender and SPG4 mutations were associated with higher urinary frequency and severity of urological involvement. QoL was overall reduced, more in women and in SPG4 mutation carriers. Almost 90% consulted a medical specialist; more than half were largely satisfied. 43.4% received oral medication and 5.7% received intravesical botulinum toxin. However, more than one-third of patients remained untreated.

Conclusion

Urinary complaints are common in HSP and should be addressed and treated.
Literature
1.
go back to reference de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB (2017) Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 16:525–551CrossRefPubMed de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB (2017) Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 16:525–551CrossRefPubMed
2.
go back to reference Braschinsky M, Zopp I, Kals M, Haldre S, Gross-Paju K (2010) Bladder dysfunction in hereditary spastic paraplegia: what to expect? J Neurol Neurosurg Psychiatry 81:263–266CrossRefPubMed Braschinsky M, Zopp I, Kals M, Haldre S, Gross-Paju K (2010) Bladder dysfunction in hereditary spastic paraplegia: what to expect? J Neurol Neurosurg Psychiatry 81:263–266CrossRefPubMed
3.
go back to reference Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC et al (2012) Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord 50:558–562CrossRefPubMed Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC et al (2012) Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord 50:558–562CrossRefPubMed
4.
go back to reference Joussain CL, Charlanes J, Even A, Falcou A, Chartier-Kastler L, Denys EP (2016) Neurogenic detrusor overactivity in patients with hereditary spastic paraplegias. Ann Phys Rehabil Med 59S:e104CrossRef Joussain CL, Charlanes J, Even A, Falcou A, Chartier-Kastler L, Denys EP (2016) Neurogenic detrusor overactivity in patients with hereditary spastic paraplegias. Ann Phys Rehabil Med 59S:e104CrossRef
5.
go back to reference Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 50:1306–1314 (discussion 1314-1305) CrossRefPubMed Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 50:1306–1314 (discussion 1314-1305) CrossRefPubMed
6.
go back to reference Yeo L, Singh R, Gundeti M, Barua JM, Masood J (2012) Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol 44:415–424CrossRefPubMed Yeo L, Singh R, Gundeti M, Barua JM, Masood J (2012) Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol 44:415–424CrossRefPubMed
7.
8.
go back to reference Schule R, Wiethoff S, Martus P et al (2016) Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Ann Neurol 79:646–658CrossRefPubMed Schule R, Wiethoff S, Martus P et al (2016) Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Ann Neurol 79:646–658CrossRefPubMed
9.
go back to reference Fjermestad KW, Kanavin OJ, Naess EE, Hoxmark LB, Hummelvoll G (2016) Health survey of adults with hereditary spastic paraparesis compared to population study controls. Orphanet J Rare Dis 11:98CrossRefPubMedPubMedCentral Fjermestad KW, Kanavin OJ, Naess EE, Hoxmark LB, Hummelvoll G (2016) Health survey of adults with hereditary spastic paraparesis compared to population study controls. Orphanet J Rare Dis 11:98CrossRefPubMedPubMedCentral
10.
go back to reference Vahter L, Braschinsky M, Haldre S, Gross-Paju K (2009) The prevalence of depression in hereditary spastic paraplegia. Clin Rehabil 23:857–861CrossRefPubMed Vahter L, Braschinsky M, Haldre S, Gross-Paju K (2009) The prevalence of depression in hereditary spastic paraplegia. Clin Rehabil 23:857–861CrossRefPubMed
11.
go back to reference Sperfeld AD, Unrath A, Kassubek J (2007) Restless legs syndrome in hereditary spastic paraparesis. Eur Neurol 57:31–35CrossRefPubMed Sperfeld AD, Unrath A, Kassubek J (2007) Restless legs syndrome in hereditary spastic paraparesis. Eur Neurol 57:31–35CrossRefPubMed
12.
go back to reference Martin JL, Williams KS, Abrams KR et al (2006) Systematic review and evaluation of methods of assessing urinary incontinence. Health Technol Assess 10:1–132, iii-ivCrossRefPubMed Martin JL, Williams KS, Abrams KR et al (2006) Systematic review and evaluation of methods of assessing urinary incontinence. Health Technol Assess 10:1–132, iii-ivCrossRefPubMed
14.
go back to reference Braschinsky M, Rannikmae K, Krikmann U et al (2011) Health-related quality of life in patients with hereditary spastic paraplegia in Estonia. Spinal Cord 49:175–181CrossRefPubMed Braschinsky M, Rannikmae K, Krikmann U et al (2011) Health-related quality of life in patients with hereditary spastic paraplegia in Estonia. Spinal Cord 49:175–181CrossRefPubMed
15.
go back to reference Visco AG, Brubaker L, Jelovsek JE et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the anticholinergic versus Botox comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28CrossRefPubMedPubMedCentral Visco AG, Brubaker L, Jelovsek JE et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the anticholinergic versus Botox comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28CrossRefPubMedPubMedCentral
16.
go back to reference Ni J, Wang X, Cao N, Si J, Gu B (2017) Is repeat botulinum toxin a injection valuable for neurogenic detrusor overactivity—a systematic review and meta-analysis. Neurourol Urodyn 37:542–553CrossRefPubMed Ni J, Wang X, Cao N, Si J, Gu B (2017) Is repeat botulinum toxin a injection valuable for neurogenic detrusor overactivity—a systematic review and meta-analysis. Neurourol Urodyn 37:542–553CrossRefPubMed
17.
go back to reference Kaviani A, Khavari R (2017) Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am 44:463–474CrossRefPubMedPubMedCentral Kaviani A, Khavari R (2017) Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am 44:463–474CrossRefPubMedPubMedCentral
18.
go back to reference Mehta S, Hill D, McIntyre A et al (2013) Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil 94:1473–1481CrossRefPubMed Mehta S, Hill D, McIntyre A et al (2013) Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil 94:1473–1481CrossRefPubMed
19.
go back to reference Knupfer SC, Schneider SA, Averhoff MM et al (2016) Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol 16:55CrossRefPubMedPubMedCentral Knupfer SC, Schneider SA, Averhoff MM et al (2016) Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol 16:55CrossRefPubMedPubMedCentral
Metadata
Title
Urinary symptoms, quality of life, and patient satisfaction in genetic and sporadic hereditary spastic paraplegia
Authors
Susanne A. Schneider
Viktoria E. Beckinger
Bettina Möller
Stephanie Knüpfer
Moritz Hamann
Günther Deuschl
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 1/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-018-9129-8

Other articles of this Issue 1/2019

Journal of Neurology 1/2019 Go to the issue